Table I.

Baseline characteristics of all patients (n=79).

	Capecitabine maintenance		HRT maintenance
Characteristics	n	%	n	%	P-value
Menopause status					0.406
Pre	12	30.8	9	22.5
Post	27	69.2	31	77.5
ECOG PS					0.372
0	23	59.0	30	75.0
1	14	35.9	9	22.5
2	2	5.1	1	2.5
HR status					0.082
Positive	28	71.8	35	87.5
Negetive	11	28.2	5	12.5
Lymph nodes, na					0.516
0–3	28	71.8	26	65.0
≥4	11	28.2	14	35.0
Her-2 status					0.876
Positiveb	6	15.4	5	12.5
Negativec	32	82.1	34	85.0
Unknown	1	2,4	1	2.5
Metastatic site
Liver	14	35.9	12	30.0	0.577
Lung	23	59.0	18	45.0	0.214
Bone	20	51.3	21	52.5	0.914
Brain	3	7.7	4	10	1.000
Soft tissue	22	56.4	30	75.0	0.082
Visceral metastasis					0.210
Yes	32	82.1	28	70.0
No	7	17.9	12	30.0
Metastatic sites, n					0.943
1	7	17.9	8	20.0
2	18	46.2	17	42.5
≥3	14	35.9	15	37.5
Disease-free interval, years					0.539
<2	13	33.3	16	40.0
≥2	26	66.7	24	60.0
Prior adjuvant chemotherapy					0.523
Taxane	20	51.3	20	50.0
Anthracycline	35	89.7	27	67.5
Prior adjuvant endocrine therapy	25	64.1	27	67.5	0.764
Prior palliative endocrine therapy	17	43.5	13	32.5	0.310

^aLymph nodes, n indicates the number of metastatic lymph nodes;

^bHR-positive status indicates estrogen and/or progesterone receptor-positive;

^cHR-negative status indicates estrogen and progesterone receptor-negative.

HRT, hormone replacement therapy; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hormone receptor; Her-2, human epidermal growth factor receptor-2.